# lung adenocarcinoma (LUAD) - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 6
- Task type: PROGNOSIS
- Tissue / sample source: lung adenocarcinoma tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: a2c9355177479f23c6c81afe1b39ba697ac131cc344bb83120b98e2c6bbfee49
- Response HTTP status: 200
- Prompt tokens: 31074
- Completion tokens: 13854
- Reasoning tokens: 0
- Total tokens: 44928
- API requests reported: 3
- Elapsed seconds: 98.235
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 957.651
- Question handoff seconds: 970.897
- Final benchmark system: E2seq; file rank 4/5; original repeat 6; model vendor: DeepSeek

---
# Multidimensional Interpretation of Prognostic Transcriptomic Data in Lung Adenocarcinoma (LUAD)

## Critical Data-Quality Warning

Before any biological interpretation, I must flag a serious technical concern. The input table contains **96 risk-associated genes and only 4 protective-associated genes** among 100 selected unique genes. Among the risk-associated genes, a large fraction show **extreme, implausible hazard ratios** (e.g., HR = 5.185e+21, a value that is mathematically degenerate), and many are pseudogenes, uncharacterized loci, unmapped Ensembl IDs, or non-coding RNAs (e.g., RBMY1F, RP11-* loci, Y_RNA, TTTY4C, MIR509-1). These extreme values (HR ≈ 10²¹, P = 0, FDR = 0) are statistically suspicious and likely reflect **quasi-complete separation** or near-zero-variance subgroups in a Cox model — a common artifact when a feature is expressed in only a very small number of samples or when the model fails to converge. The ledger itself flags one gene (Y_RNA) as having a direction-conflict across 163 rows, and 2 duplicated genes/probes were detected.

I will therefore: (1) treat the extreme-HR genes as **statistically unreliable direct evidence**, (2) focus biological interpretation on the genes with **finite, plausible HRs and non-zero P/FDR values** (the lower portion of the table), and (3) explicitly label which conclusions rest on external evidence versus direct cohort statistics.

---

## 1. Overall Biological Interpretation

After excluding the degenerate-HR genes (HR ≈ 10²¹), the interpretable portion of the cohort consists of ~30 genes with finite HRs and FDR ≤ 0.01. Among these, the dominant signal is a **risk-associated (HR > 1) program** centered on:

- **Wnt/developmental signaling**: DKK1 (HR=1.48), TLE1 (HR=1.48), PITX3 (HR=1.43), VAX1 (HR=1.33), CREG2 (HR=1.33)
- **Glycosylation/carbohydrate metabolism**: FUT4 (HR=1.40), CMAHP (HR=0.71, protective)
- **Cytoskeletal/Rho-GTPase signaling**: RHOF (HR=1.40), RGS20 (HR=1.35)
- **Cellular adhesion/keratinization**: KRT6A (HR=1.39), LDLRAD3 (HR=1.42), ITGB1-DT (HR=1.30)
- **Long non-coding RNAs**: LINC01312, LINC02178, LINC01910, LINC02323, LINC02802, LINC00707 (all HR ≈ 1.3–1.4)

The overall theme is a **risk-associated transcriptional program combining aberrant developmental/Wnt signaling, altered glycosylation, Rho-family cytoskeletal remodeling, and epithelial/keratinocyte-like differentiation** — features that collectively suggest a more aggressive, poorly differentiated, or stem-like LUAD phenotype. The protective genes (CRNDE, RBMXP1, CMAHP) are too few to define a coherent protective program, and their interpretation is limited.

**Critical caveat**: Because the extreme-HR pseudogene/lincRNA cluster dominates the cohort numerically, the "overall" theme is heavily weighted by non-coding and unannotated loci whose biological roles are largely unknown. The coherent protein-coding signal above is the most defensible interpretation, but it represents only a subset of the selected genes.

---

## 2. Core Biological Programs

### Program 1: Wnt/Developmental Signaling Activation
- **Direction**: Risk-associated (HR > 1)
- **Supporting genes**: DKK1 (HR=1.48), TLE1 (HR=1.48), PITX3 (HR=1.43), VAX1 (HR=1.33), CREG2 (HR=1.33)
- **Pathway**: Wnt signaling pathway (KEGG); Regulation of Wnt signaling (GO:0030111); Positive regulation of Wnt signaling, planar cell polarity (GO:2000096)
- **Explanation**: DKK1 is a canonical Wnt antagonist, yet its elevated expression with poor survival is paradoxical and may reflect feedback activation in a Wnt-high tumor. TLE1 is a transcriptional corepressor that modulates Wnt/β-catenin and Notch targets. PITX3 and VAX1 are homeodomain transcription factors involved in developmental patterning, consistent with an aberrantly activated developmental program.
- **Evidence strength**: Moderate. Multiple independent protein-coding genes converge on Wnt/developmental biology, and the pathway annotation is consistent. **Limitation**: DKK1's role is context-dependent (can be tumor-suppressive or pro-metastatic depending on the Wnt pathway branch); no independent-cohort statistic is available.

### Program 2: Rho-GTPase / Cytoskeletal Remodeling
- **Direction**: Risk-associated
- **Supporting genes**: RHOF (HR=1.40), RGS20 (HR=1.35)
- **Pathway**: Regulation of actin cytoskeleton (KEGG); Small GTPase-mediated signal transduction (GO:0007264)
- **Explanation**: RHOF (RhoF) is a Rho-family GTPase involved in actin organization and cell migration; its high expression predicts worse OS in AML (PMID 34405015). RGS20 is a regulator of G-protein signaling that modulates Gα(i/z) signaling (Reactome: R-BTA-418594/418597) and interacts with GNAZ, GNB5, GNAI2, GNAQ (STRING, confidence 0.80–0.95). Together they point to cytoskeletal plasticity and GPCR-coupled signaling that may promote invasion.
- **Evidence strength**: Moderate. Two genes with plausible mechanism; RHOF has independent literature support in another malignancy. **Limitation**: Only two genes; no direct interaction evidence between RHOF and RGS20 in this dataset.

### Program 3: Aberrant Glycosylation / Fucosylation
- **Direction**: Mixed — FUT4 risk (HR=1.40), CMAHP protective (HR=0.71)
- **Supporting genes**: FUT4, CMAHP
- **Pathway**: Mannose-type O-glycan biosynthesis (KEGG); Glycosphingolipid biosynthesis (KEGG)
- **Explanation**: FUT4 encodes an α1,3-fucosyltransferase that adds fucose to glycans, a modification frequently upregulated in cancer and associated with altered cell adhesion and immune evasion. CMAHP (cytidine monophospho-N-acetylneuraminic acid hydroxylase pseudogene) is protective, suggesting an opposing sialylation-related signal. The opposing directions are biologically plausible if fucosylation promotes aggressiveness while CMAHP-related sialic acid processing is protective.
- **Evidence strength**: Weak-to-moderate. Only two genes; pathway membership is inferred from annotation, not computed enrichment. **Limitation**: CMAHP is a pseudogene; its protective association may reflect a proxy or technical artifact.

### Program 4: Epithelial/Keratinocyte Differentiation and Adhesion
- **Direction**: Risk-associated
- **Supporting genes**: KRT6A (HR=1.39), LDLRAD3 (HR=1.42), ITGB1-DT (HR=1.30)
- **Pathway**: Cell junction disassembly (GO:0150146); Keratinization (GO:0031424)
- **Explanation**: KRT6A is a keratin induced during epithelial stress and is a biomarker in several contexts (PMID 42216026). LDLRAD3 is a LDL-receptor family member implicated in cell adhesion and signaling. ITGB1-DT is a divergent transcript of ITGB1 (integrin β1) and has been proposed as a LUAD biomarker through the ITGB1-DT/ARNTL2 axis (PMID 34906142).
- **Evidence strength**: Moderate. ITGB1-DT has independent LUAD-specific literature support. **Limitation**: ITGB1-DT is a lncRNA; its mechanism is regulatory rather than direct protein interaction; KRT6A upregulation may reflect tumor cell composition (e.g., squamous differentiation within LUAD) rather than a tumor-intrinsic program.

### Program 5: Non-Coding RNA / LincRNA Risk Signature
- **Direction**: Risk-associated
- **Supporting genes**: LINC01312, LINC02178, LINC01910, LINC02323, LINC02802, LINC00707 (all HR ≈ 1.3–1.4)
- **Pathway**: No single canonical pathway; these are regulatory RNAs
- **Explanation**: A consistent set of long intergenic non-coding RNAs each associates with worse OS. While individual lncRNA mechanisms are poorly defined, their coordinate association suggests either a shared regulatory network (e.g., a common upstream transcription factor) or a technical artifact (e.g., alignment/mapping issues or expression in a specific cell subset).
- **Evidence strength**: Weak biological mechanism, but statistically consistent (all FDR ≤ 0.001). **Limitation**: No pathway annotation; the risk is that these are correlated with tumor purity or stromal content rather than being causal drivers.

---

## 3. Key Genes and Interaction Modules

### 1. DKK1 + TLE1 (Wnt module)
- **Statistics**: DKK1 HR=1.48 (FDR=3.5e-07); TLE1 HR=1.48 (FDR=2.5e-05)
- **Role**: Canonical Wnt antagonist (DKK1) and transcriptional corepressor (TLE1) — together suggesting disrupted Wnt/β-catenin homeostasis.
- **Relationship**: **Pathway co-membership** (both in Wnt signaling); no direct physical interaction evidence in this dataset.

### 2. RHOF + RGS20 (Rho/GPCR module)
- **Statistics**: RHOF HR=1.40 (FDR=4.0e-04); RGS20 HR=1.35 (FDR=5.8e-04)
- **Role**: Rho-family GTPase (cytoskeletal remodeling) and RGS protein (GPCR signal termination).
- **Relationship**: **Indirect/putative** — both participate in small GTPase signaling but no direct interaction is known. RGS20 interacts with GNAZ/GNB5/GNAI2/GNAQ (STRING), which are upstream of Rho-family effectors; this is a plausible **pathway-level** connection.

### 3. FUT4 + CMAHP (Glycosylation module)
- **Statistics**: FUT4 HR=1.40 (FDR=2.9e-04); CMAHP HR=0.71 (FDR=5.8e-04, protective)
- **Role**: Fucosyltransferase (risk) vs. sialic acid hydroxylase pseudogene (protective) — opposing glycan-modifying signals.
- **Relationship**: **Pathway co-membership** in glycan biosynthesis; no direct interaction.

### 4. ITGB1-DT + KRT6A (Epithelial/adhesion module)
- **Statistics**: ITGB1-DT HR=1.30 (FDR=1.5e-04); KRT6A HR=1.39 (FDR=2.8e-04)
- **Role**: Integrin-associated lncRNA and stress keratin — epithelial identity/adhesion.
- **Relationship**: **Co-expression/putative** — no direct interaction evidence; both may reflect a common epithelial differentiation state.

### 5. PITX3 + VAX1 (Developmental transcription factor module)
- **Statistics**: PITX3 HR=1.43 (FDR=3.5e-11); VAX1 HR=1.33 (FDR=9.2e-06)
- **Role**: Homeodomain TFs normally active in development; aberrant reactivation may drive dedifferentiation.
- **Relationship**: **Pathway co-membership** (both are developmental TFs); no direct interaction evidence in this dataset.

### 6. RBMXP1 (protective outlier)
- **Statistics**: HR=0.21 (FDR=1.6e-17) — the strongest protective signal in the cohort.
- **Role**: RNA-binding motif protein, X-linked pseudogene. Its strong protective association is notable but mechanistically unclear.
- **Relationship**: None identified in this dataset.

---

## 4. Validation Priorities

### Priority 1: Wnt/Developmental Program — Mechanistic Hypothesis
- **Why**: Multiple independent protein-coding genes (DKK1, TLE1, PITX3, VAX1) converge on Wnt/developmental signaling with consistent risk direction.
- **Current evidence**: Direct HRs with FDR ≤ 2.5e-05; pathway annotation supports Wnt involvement.
- **External evidence**: DKK1 and TLE1 have extensive cancer literature; however, DKK1's role is context-dependent and can be anti-tumorigenic.
- **Next step**: In vitro Wnt reporter assays (TOP/FOP-flash) in LUAD cell lines with DKK1/TLE1 knockdown; examine β-catenin localization.
- **Status**: **Supported hypothesis** (not established — no causal experiment or independent cohort statistic).

### Priority 2: RHOF/RGS20 Cytoskeletal Module — Mechanistic + Therapeutic Target
- **Why**: RHOF has independent literature support for worse OS in AML (PMID 34405015); Rho-GTPase pathways are druggable.
- **Current evidence**: HR=1.40 (RHOF) and HR=1.35 (RGS20), both FDR ≤ 5.8e-04.
- **External evidence**: STRING shows RGS20 interactions with Gα subunits; RHOF literature in AML.
- **Next step**: Migration/invasion assays (transwell, 3D Matrigel) after RHOF knockdown in LUAD cells; test whether RGS20 modulates RHOF activity.
- **Status**: **Exploratory hypothesis** — the association is direct, but the mechanistic link between RGS20 and RHOF is untested.

### Priority 3: ITGB1-DT as a LUAD Biomarker — Biomarker
- **Why**: Independent LUAD-specific literature (PMID 34906142) proposes ITGB1-DT/ARNTL2 as a biomarker; our data show HR=1.30 (FDR=1.5e-04).
- **Current evidence**: Direct risk association.
- **External evidence**: Literature support in LUAD; also proposed in breast cancer (PMID 37690573).
- **Next step**: Validate in an independent LUAD cohort (e.g., TCGA-LUAD RNA-seq or a clinical qPCR cohort) with multivariate Cox adjustment for stage/age/sex.
- **Status**: **Supported hypothesis** (direction concordant with literature, but no independent cohort statistic in this analysis).

### Priority 4: Extreme-HR Gene Cluster — Confounding/Composition Check
- **Why**: The ~70 genes with HR ≈ 5.2e+21 are statistically degenerate and likely reflect quasi-separation, low expression prevalence, or technical artifacts. These must be resolved before any biological claim is made about them.
- **Current evidence**: HR=5.185e+21, P=0, FDR=0 for many pseudogenes/lincRNAs (e.g., RBMY1F, RP11-998D10.4, Y_RNA).
- **External evidence**: None — these are uncharacterized loci with no pathway annotation.
- **Next step**: Examine expression prevalence (fraction of samples with non-zero counts); refit Cox models with Firth's penalized likelihood or exclude rare features; check whether these genes are Y-chromosome or sex-specific (e.g., RBMY1F, TTTY4C, USP9YP3 are Y-linked — this could reflect sex imbalance).
- **Status**: **Exploratory hypothesis** — the extreme HRs are almost certainly artifacts, not true biology.

### Priority 5: FUT4/CMAHP Glycosylation Axis — Mechanistic + Biomarker
- **Why**: Opposing directions (risk vs. protective) in glycan biosynthesis suggest a functionally meaningful balance between fucosylation and sialylation.
- **Current evidence**: FUT4 HR=1.40, CMAHP HR=0.71, both FDR ≤ 5.8e-04.
- **External evidence**: FUT4 fucosylation is implicated in cancer adhesion/immune evasion; CMAHP is a pseudogene with limited literature.
- **Next step**: Lectin-based glycan profiling (e.g., AAL for fucose) in LUAD tissues stratified by FUT4 expression; test FUT4 knockdown effects on adhesion/immune evasion.
- **Status**: **Exploratory hypothesis** — direct association, but mechanistic and independent validation are lacking.

---

## 5. Evidence Grounding

| Claim | Direct Input Evidence | Pathway/Ontology | Interaction/Regulatory | Disease/Literature | Independence Assessment |
|---|---|---|---|---|---|
| Wnt/developmental risk program | DKK1, TLE1, PITX3, VAX1 HRs (FDR ≤ 2.5e-05) | KEGG Wnt pathway; GO:0030111 | None direct | DKK1/TLE1 cancer literature | Literature and pathway annotations may share underlying publications; not fully independent |
| Rho/cytoskeletal risk | RHOF HR=1.40, RGS20 HR=1.35 | GO:0007264; Reactome Gα signaling | STRING: RGS20–GNAZ/GNB5/GNAI2/GNAQ | RHOF in AML (PMID 34405015) | STRING predictions and literature may overlap; RHOF AML evidence is a different disease |
| Glycosylation (FUT4 risk, CMAHP protective) | FUT4 HR=1.40, CMAHP HR=0.71 | KEGG glycan biosynthesis | None | Limited | Weak; only two genes |
| ITGB1-DT biomarker | HR=1.30 (FDR=1.5e-04) | None specific | Regulatory (lncRNA of ITGB1) | LUAD literature (PMID 34906142) | Literature is independent of our cohort but no external statistic supplied |
| Extreme-HR cluster | HR≈5.2e+21, P=0 | None | None | None | **Insufficient evidence** — likely statistical artifact |

**Important**: No independent-cohort statistic (HR, P, FDR from a separate dataset) was supplied. Therefore, **external statistical validation was not performed**. All literature and database support is contextual, not replication.

---

## 6. Limitations and Alternative Explanations

1. **Quasi-separation / model non-convergence**: The HR ≈ 10²¹ values are not biologically interpretable. They likely arise from features expressed in a tiny fraction of samples (or in a single sex, e.g., Y-linked genes RBMY1F, TTTY4C, USP9YP3) causing Cox model separation. **Investigation**: Check expression prevalence; use Firth correction; stratify by sex.

2. **Sex and Y-chromosome bias**: Multiple Y-linked genes (RBMY1F, TTTY4C, USP9YP3, CDY10P) appear as extreme-risk genes. If the cohort has imbalanced sex ratios or if Y-linked genes are expressed only in male tumors, the "risk" association may reflect sex or tumor subtype rather than a biological program. **Investigation**: Stratify by sex; confirm Y-chromosome gene expression is not an alignment artifact.

3. **Tumor purity and cell composition**: KRT6A (keratinocyte marker) and the many lncRNA signals could reflect differences in tumor differentiation, squamous contamination, or stromal/immune content rather than a tumor-intrinsic program. **Investigation**: Estimate tumor purity (e.g., ESTIMATE, ABSOLUTE); perform single-cell or deconvolution analysis.

4. **Disease severity / stage confounding**: The input provides no stage, grade, or treatment information. If high-HR genes correlate with advanced stage, the OS association may be stage-driven rather than independent. **Investigation**: Multivariate Cox models adjusting for stage, age, sex, and smoking status.

5. **Association vs. causation**: All conclusions here are associative. The presence of a drug targeting a pathway (e.g., Wnt inhibitors) does not establish therapeutic efficacy in LUAD. Mechanistic validation (knockdown, reporter assays, xenografts) is required before any causal or therapeutic claim.

---

## Summary

The interpretable signal in this LUAD OS cohort points to a **risk-associated program of aberrant Wnt/developmental signaling, Rho-family cytoskeletal remodeling, altered glycosylation, and epithelial/keratinocyte-like differentiation**, with ITGB1-DT, DKK1, TLE1, RHOF, and FUT4 as representative candidates. However, the cohort is dominated by statistically degenerate extreme-HR genes (mostly pseudogenes and unannotated lncRNAs) that are almost certainly technical artifacts, and the protective arm is too small to define a coherent protective program; external statistical validation was not performed, so these conclusions should be treated as supported or exploratory hypotheses rather than established evidence.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=55, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 53/100 selected items (records returned); cbioportal 51/100 selected items (records returned); chembl 16/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 6/100 selected items (records returned); clinvar 30/100 selected items (records returned); ensembl 11/100 selected items (partially returned; some queries failed); europepmc 362 articles / initial full-cohort RAG 100 queries + 4 current-round queries; some queries failed; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 56/100 selected items (partially returned; some queries failed); intact 18/100 selected items (records returned); mygene 59/100 selected items (records returned); omnipath 3/100 selected items (records returned); opentargets 55/100 selected items (records returned); pubmed 202 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 17/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 17/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 2/100 selected items (records returned); string 14/100 selected items (records returned); trrust 4/100 selected items (records returned)
